Dupilumab is in development for the treatment of children aged ≥ 6 to < 12 years with severe atopic dermatitis (AD) uncontrolled with currently available therapies. AD is a chronic inflammatory skin disease that affects both children and adults and is characterised by redness, itchiness, and scaling of the skin. Some people only have small patches of dry skin, but others may experience widespread red, inflamed skin all over the body. Patients with moderate to severe AD could come across with sleep disturbances, anxiety, depression, and poor quality of life. Currently, the management of AD involves the removal or treatment of trigger factors that contribute to the development of the disease.
Dupilumab acts by blocking certain proteins called interleukin-4 (IL-4) and interleukin-13 (IL-13) and mediating the pathways involved in the inflammatory process in AD. Dupilumab is taken subcutaneously (SC) and is currently licensed for the treatment of moderate to severe AD in adults who are candidates for systemic therapy. If licensed, dupilumab will offer an additional treatment option for children aged ≥ 6 to < 12 years with severe AD.
Secukinumab is a monoclonal antibody, a type of protein, designed to recognise and attach to a messenger molecule in the immune system called interleukin 17A. This molecule is involved in the inflammation and other immune system processes that cause psoriasis. By attaching to and blocking the action of interleukin 17A, secukinumab reduces the activity of the immune system and the symptoms of the disease. If licensed, secukinumab will offer a first-line systemic treatment option in children and adolescents with moderate to severe plaque psoriasis in patients who are candidates for systemic therapy.